LV232
/ Vigonvita Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 18
Of
18
Go to page
1
November 25, 2025
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=49 | Completed | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Dec 2024 | Trial primary completion date: Oct 2025 ➔ Dec 2024
Trial completion • Trial completion date • Trial primary completion date
June 10, 2025
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Vigonvita Life Sciences | Trial primary completion date: May 2025 ➔ Jan 2025 | Recruiting ➔ Completed
Trial completion • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
April 25, 2025
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
(clinicaltrials.gov)
- P2 | N=400 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026
Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
February 28, 2025
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Oct 2025
Trial completion date • Trial primary completion date
February 28, 2025
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Vigonvita Life Sciences | N=48 ➔ 80 | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Oct 2025
Enrollment change • Trial completion date • Trial primary completion date
February 18, 2025
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of Major Depressive Disorder (MDD)
(clinicaltrials.gov)
- P2 | N=500 | Not yet recruiting | Sponsor: Vigonvita Life Sciences
New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
February 16, 2025
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025
Trial completion date • Trial primary completion date
February 16, 2025
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025
Trial completion date • Trial primary completion date
February 14, 2025
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
(clinicaltrials.gov)
- P1 | N=8 | Recruiting | Sponsor: Vigonvita Life Sciences | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025
Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
October 15, 2024
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2024 ➔ Dec 2024
Enrollment closed • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
October 01, 2024
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Dec 2024
Trial completion date • Trial primary completion date
October 01, 2024
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jul 2024 ➔ Dec 2024
Trial completion date • Trial primary completion date
June 26, 2024
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
(clinicaltrials.gov)
- P1 | N=8 | Not yet recruiting | Sponsor: Vigonvita Life Sciences
New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
April 24, 2024
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting
Enrollment open
April 24, 2024
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024
Trial completion date • Trial primary completion date
February 28, 2024
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Vigonvita Life Sciences
New P1 trial
October 17, 2023
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting
Enrollment open
October 06, 2023
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Vigonvita Life Sciences
New P1 trial
1 to 18
Of
18
Go to page
1